Table 2 Sociodemographic characteristics, baseline clinical characteristics and psychopathology measures by resistance to antipsychotic treatment.
NonTRS (N = 31) | TRS (N = 13) | ||||||
|---|---|---|---|---|---|---|---|
Mean or N | SD or % | Mean or N | SD or % | t/\({X}^{2}\) | p | Significant comparisonsa | |
Age at onset | 33.5 | 17.3 | 26.1 | 7.7 | 1.465 | 0.150 | |
Female sex | 13 | 41.2% | 6 | 46.1% | 0.066 | 0.797 | |
Substance use last 6 months | 19 | 61.1% | 6 | 46.1% | 0.855 | 0.355 | |
Smoking | 17 | 54.8% | 4 | 30.7% | 2.127 | 0.145 | |
Cannabis use | 14 | 45.2% | 5 | 38.5% | 0.168 | 0.682 | |
Alcohol use | 9 | 29.0% | 2 | 15.4% | 1.460 | 0.482 | |
First degree family history of psychiatric disease | 16 | 51.6% | 5 | 38.5% | 0.635 | 0.426 | |
DUI (days) | 141.0 | 149.2 | 452.2 | 564.2 | -2.881 | 0.006 | TRS>nonTRS |
DUP (days) | 46.3 | 73.0 | 37.2 | 44.0 | 0.415 | 0.680 | |
Acute onset psychosis | 9 | 29.0% | 7 | 53.8% | 2.437 | 0.118 | |
Previous life stressful events | 13 | 41.9% | 5 | 38.5% | 0.046 | 0.831 | |
Duration of the index admission (days) | 18.8 | 10.8 | 35.3 | 22.64 | -3.283 | 0.002 | TRS>nonTRS |
Previous GAF | 72.8 | 13.1 | 66.1 | 12.2 | 1.562 | 0.126 | |
GAF admission | 31.3 | 7.4 | 28.4 | 8.2 | 1.175 | 0.247 | |
GAF discharge | 62.9 | 9.6 | 60.4 | 5.6 | 0.865 | 0.392 | |
Prodromal symptoms | 19 | 61.3% | 9 | 69.2% | 0.250 | 0.617 | |
PANSS Positive score | 24.1 | 3.9 | 27.7 | 5.4 | -2.508 | 0.016 | TRS>nonTRS |
PANSS Negative score | 17.2 | 7.0 | 22.7 | 9.3 | -2.116 | 0.040 | TRS>nonTRS |
PANSS General score | 40.2 | 7.0 | 53.2 | 22.2 | -2.962 | 0.005 | TRS>nonTRS |
PANSS Total score | 81.5 | 13.3 | 103.6 | 32.2 | -3.246 | 0.002 | TRS>nonTRS |
CSF total proteins | 29.7 | 8.1 | 25.2 | 7.8 | 1.685 | 0.099 | |
CSF LDH | 29.4 | 13.2 | 19.2 | 8.3 | 2.552 | 0.014 | TRS<nonTRS |
CSF glucose | 65.1 | 7.8 | 66.4 | 6.4 | -0.513 | 0.610 | |
Poor early antipsychotic response | 3 | 9.7% | 6 | 46.1% | 7.490 | 0.006 | TRS>nonTRS |
Antipsychotic treatment at assessment | |||||||
Olanzapine | 11 | 35.5% | 8 | 61.5% | 3.220 | 0.359 | |
Paliperidone | 6 | 19.4% | 2 | 15.4% | |||
Risperidone | 11 | 35.5% | 3 | 23.1% | |||
Aripiprazole | 3 | 9,7% | 0 | 0% | |||
